SFX by Ex Libris Inc.

Title:	A Novel Chromosomal Translocation t(4; 14)(p16.3; q32) in Multiple Myeloma Involves the Fibroblast Growth-Factor Receptor 3 Gene
Source:	Blood [0006-4971] Richelda, Raffaella yr:1997

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Tan, D. "An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era." American journal of hematology 85.10 (2010): 752-756.
description	2.	Stec, I. "WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma." Human Molecular Genetics 7.7 (1998): 1071-82.
description	3.	Put, N. "Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia." Genes, chromosomes & cancer 49.11 (2010): 991-997.
description	4.	BalcÃrkovÃ, J. "Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma." Cancer genetics and cytogenetics 192.2 (2009): 68-72.
description	5.	Dascalescu, C M. "Interphase FISH: a rapid method for detecting malignant plasma cells in multiple myeloma patients submitted to autologous transplantation." Bone marrow transplantation 23.7 (1999): 687-694.
description	6.	Pei, H. "MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites." Nature 470.7332 (2011): 124-128.
description	7.	Sutcliffe, Elissa L L. "Dynamic histone variant exchange accompanies gene induction in T cells." Molecular and cellular biology 29.7 (2009): 1972-86.
description	8.	Chesi, M. "The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts." Blood 92.9 (1998): 3025-34.
description	9.	Peters, Antoine H.F.M. H. "Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability." Cell 107.3 (2001): 323-337.
description	10.	Bergemann, Andrew D D. "The etiology of Wolf-Hirschhorn syndrome." Trends in genetics 21.3 (2005): 188-95.
description	11.	Vekemans, K. "The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome." British journal of haematology 149.6 (2010): 901-904.
description	12.	Ishigaki, T. "Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case." Cancer genetics and cytogenetics 201.1 (2010): 62-65.
description	13.	Sandecka, H. "Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy." Biology of blood and marrow transplantation 16.4 (2010): 548-554.
description	14.	Battaglia, A. "Health supervision and anticipatory guidance of individuals with Wolf-Hirschhorn syndrome." American journal of medical genetics 89.2 (1999): 111-5.
description	15.	Campos, Eric I. "Histones: annotating chromatin." Annual Review of Genetics 43.1 (2009): 559-599.
description	16.	Nielsen, S J J. "Rb targets histone H3 methylation and HP1 to promoters." Nature 412.6846 (2001): 561-5.
description	17.	Santos, F. "Epigenetic Marking Correlates with Developmental Potential in Cloned Bovine Preimplantation Embryos." Current biology 13.13 (2003): 1116-21.
description	18.	Olsson, L. "Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011." Leukemia 28.2 (2014): 302-310.
description	19.	Lauring, J. "The multiple myeloma–associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity." Blood 111.2 (2008): 856-.
description	20.	Chen, M. "p53 Nuclear Expression Correlates With Hemizygous TP53 Deletion and Predicts an Adverse Outcome for Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide." American journal of clinical pathology 137.2 (2012): 208-212.